Preclinical study models of psoriasis: State-of-the-art techniques for testing pharmaceutical products in animal and nonanimal models

Int Immunopharmacol. 2023 Apr:117:109945. doi: 10.1016/j.intimp.2023.109945. Epub 2023 Mar 3.

Abstract

Local and systemic treatments exist for psoriasis, but none can do more than control its symptoms because of its numerous unknown mechanisms. The lack of validated testing models or a defined psoriatic phenotypic profile hinders antipsoriatic drug development. Despite their intricacy, immune-mediated diseases have no improved and precise treatment. The treatment actions may now be predicted for psoriasis and other chronic hyperproliferative skin illnesses using animal models. Their findings confirmed that a psoriasis animal model could mimic a few disease conditions. However, their ethical approval concerns and inability to resemble human psoriasis rightly offer to look for more alternatives. Hence, in this article, we have reported various cutting-edge techniques for the preclinical testing of pharmaceutical products for the treatment of psoriasis.

Keywords: In-vitro model; In-vivo model; Preclinical model; Psoriasis; Testing.

Publication types

  • Review

MeSH terms

  • Animals
  • Chronic Disease
  • Dermatologic Agents*
  • Disease Models, Animal
  • Humans
  • Models, Animal
  • Pharmaceutical Preparations
  • Psoriasis* / drug therapy
  • Skin

Substances

  • Dermatologic Agents
  • Pharmaceutical Preparations